Latest Regulatory Filings News

Rhythm Biosciences bolstered its financial position with a $5.2 million option underwriting while accelerating commercial adoption of its ColoSTAT® colorectal cancer test and advancing geneType™ partnerships internationally in Q4 FY26.

Volt Group has delivered a record $5.1 million in half year revenue receipts for HY26, more than doubling prior year results, driven by strong contributions from its 4D Delta acquisition and solid performances across Wescone and EcoQuip.

Cleo Diagnostics has entered the critical Analytical Validation phase for its ovarian cancer blood test, progressing toward an FDA 510(k) submission targeted for the first half of 2027. The company also secured a U.S. reimbursement pathway to support early market entry post-clearance, backed by a cash balance of A$6.2 million.

EQ Resources delivered a breakout quarter with A$79 million revenue and A$22.5 million operating cash flow, driven by a 176% production surge at Mt Carbine and soaring tungsten prices. The company greenlit a major expansion to double crushing capacity, targeting commissioning in Q3 FY2027.

European Lithium (ASX: EUR) has obtained a crucial ASX waiver allowing it to cancel unlisted options and performance rights without shareholder approval, smoothing the path for its acquisition by NASDAQ-listed Critical Metals Corp (NASDAQ: CRML).

EBR Systems has launched the WiSE Coupler in the US, a new accessory designed to improve the implantation of its wireless cardiac pacing electrode. The device has FDA clearance and was piloted in 10 procedures, marking another step in the company’s US commercial expansion.

NewPeak Metals has completed the initial phase of its capital raising, issuing nearly 50 million shares for $0.64 million. A shareholder meeting is scheduled for August to approve a further $2.86 million conditional placement.

Noxopharm reported significant progress in its Sofra technology, highlighting enhanced cancer drug potential and preparations for a US FDA clinical trial, while managing tight cash reserves.

Optiscan Imaging has kicked off a US clinical trial with Mayo Clinic to test its InVue and InForm devices in breast conserving surgery, aiming to generate data for FDA 510(k) submissions and validate a new surgical-pathology workflow.

Paradigm Biopharmaceuticals has strengthened its balance sheet with a combined $5.75 million cash inflow from Australian Government R&D tax incentives, supporting its pivotal Phase 3 osteoarthritis trial and regulatory efforts.

Ceretas Limited is raising $8 million through an IPO to fund clinical trials and development of its novel therapeutic ultrasound device targeting Alzheimer’s disease symptoms.

Recce Pharmaceuticals secured a non-binding term sheet with a major Middle Eastern pharma for its diabetic foot infection treatment and raised A$4 million to fund pivotal Phase 3 trials in Australia and Indonesia.